Loading
Urinary Tract Infections Management · Journal article
Frontiers in Urology · September 2, 2026
Raises a question worth testing. It does not answer one.
This narrative review examines whether dysbiosis of the gut microbiota may contribute to benign prostatic hyperplasia through mechanisms including altered short-chain fatty acid production, increased lipopolysaccharide translocation, and immune dysregulation. The current evidence base is largely associative and mechanistic, with limited direct human evidence, and the authors identify this gap as a priority for future research.
Narrative review. Patients with benign prostatic hyperplasia; review also addresses general gut microbiota function in chronic inflammatory and metabolic disease..
Alterations in microbial composition and function have been associated with numerous chronic inflammatory and metabolic disorders. Emerging clinical and preclinical evidence suggests gut dysbiosis may be associated with prostate enlargement and lower urinary tract symptoms. Proposed mechanisms include altered short-chain fatty acid production, impaired intestinal barrier integrity with increased lipopolysaccharide translocation, Toll-like receptor signaling, and changes in tryptophan and serotonin metabolism.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
Clinicians should recognize that while the gut–prostate axis is an area of emerging research interest, the evidence linking dysbiosis to BPH pathogenesis remains preliminary and largely mechanistic. Current data are insufficient to guide clinical practice changes or microbiota-targeted interventions for BPH.
A narrative review synthesizing emerging preclinical and associative clinical evidence for a putative gut–prostate axis in BPH, acknowledging that current evidence remains largely mechanistic and associative with few direct human studies.
As stated by the source record.
Clinicians should recognize that while the gut–prostate axis is an area of emerging research interest, the evidence linking dysbiosis to BPH pathogenesis remains preliminary and largely mechanistic. Current data are insufficient to guide clinical practice changes or microbiota-targeted interventions for BPH.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Benign prostatic hyperplasia (BPH) is a common age-related condition characterized by stromal and epithelial proliferation within the prostate and is influenced by androgen signaling, ageing, obesity, metabolic dysfunction, and inflammation. Increasing interest has focused on whether the gut microbiota may contribute to these processes through a putative gut–prostate axis. The human gut contains a complex microbial ecosystem comprising thousands of bacterial species whose metabolites and immune-modulatory activities influence host physiology. Alterations in microbial composition and function have been associated with numerous chronic inflammatory and metabolic disorders. Emerging clinical and preclinical evidence suggests that gut dysbiosis may also be associated with prostate enlargement and lower urinary tract symptoms. Proposed mechanisms include altered production of short-chain fatty acids, impaired intestinal barrier integrity with increased lipopolysaccharide translocation, Toll-like receptor signaling, changes in tryptophan and serotonin metabolism, vagal pathways, and systemic cytokine-mediated inflammation. However, current evidence remains largely associative and mechanistic, with relatively few human studies directly linking alterations in the gut microbiota to BPH pathogenesis. This narrative review examines current evidence supporting the gut–prostate axis in BPH, evaluates potential biological mechanisms such as the vagus nerve and tryptophan, discusses dietary influences on microbiota composition, and highlights limitations in the existing literature together with priorities for future research and therapeutic development.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.